Intelligent Bio Solutions (INBS) Current Deferred Revenue (2021 - 2025)

Intelligent Bio Solutions has reported Current Deferred Revenue for 5 years, with the latest figure at $271780.0 in Q2 2025.

• For the quarter ending Q2 2025, Current Deferred Revenue changed N/A year-over-year to $271780.0; the trailing twelve-month figure through Jun 2025 stood at $271780.0 (changed N/A YoY), and the FY2025 full-year result was $271780.0, changed N/A from the prior year.
• Current Deferred Revenue for Q2 2025 stood at $271780.0, down from $2.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $4.7 million in Q2 2021, with the low at $60413.0 in Q3 2022.
• Average Current Deferred Revenue over 5 years is $2.1 million, with a median of $2.3 million recorded in 2024.
• Year-over-year, Current Deferred Revenue slumped 96.7% in 2022 and soared 3609.35% in 2023.
• Tracing INBS's Current Deferred Revenue over 5 years: stood at $3.4 million in 2021, then slumped by 37.08% to $2.2 million in 2022, then grew by 12.95% to $2.4 million in 2023, then slipped by 5.44% to $2.3 million in 2024, then tumbled by 88.18% to $271780.0 in 2025.
• The last three Current Deferred Revenue figures came in at $271780.0 (Q2 2025), $2.3 million (Q1 2025), and $2.3 million (Q4 2024), per Business Quant data.

Peer Comparison